Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Study Identifier
CFFC-OB-11
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Results Available
Scientific Result Summary
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
N/A
Sex
Female & Male
Age
0 Months - 99 Years
Protocol Summary
This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be followed at their regular clinical care visits over a 10-year period and approached if they develop symptoms of fibrosing colonopathy for collection and use of further detailed information.
Study Locations
Location
Status
Location
Children's Hospital of Alabama /ID# 78920
Birmingham, Alabama, United States, 35233
Status
Not applicable
Location
Alaska Medical Center /ID# 79256
Anchorage, Alaska, United States, 99508
Status
Not applicable
Location
Phoenix Children's Hospital /ID# 78906
Phoenix, Arizona, United States, 85016-7710
Status
Not applicable
Location
University of Arizona Cancer Center - North Campus /ID# 78939
Tucson, Arizona, United States, 85719-1478
Status
Not applicable
Location
Arkansas Children's Hospital /ID# 79265
Little Rock, Arkansas, United States, 72202
Status
Not applicable
Location
University of Arkansas for Medical Sciences /ID# 76785
Little Rock, Arkansas, United States, 72205
Status
Not applicable
Showing {first} - {last} of {total} Results